Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Health Guard Biotechnology's earnings before interest and taxes (EBIT) for the
three
months ended in Jun. 2026 was ¥-39.35 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was ¥-507.48 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Beijing Health Guard Biotechnology's annualizedROC % for the quarter that ended in Jun. 2026 was -10.46%.
Beijing Health Guard Biotechnology's annualizedROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -16.59%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Beijing Health Guard Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -28.10%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Health Guard Biotechnology EBIT Related Terms
Beijing Health Guard Biotechnology EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Beijing Health Guard Biotechnology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Health Guard Biotechnology EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Health Guard Biotechnology's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Beijing Health Guard Biotechnology's EV-to-EBIT falls into.
Beijing Health Guard Biotechnology EBIT Calculation
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-507.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Health Guard Biotechnology (BJSE:920575) has a EBIT of ¥-507.48 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Beijing Health Guard Biotechnology.
Is Beijing Health Guard Biotechnology's EBIT too high?
Beijing Health Guard Biotechnology's current EBIT is ¥-507.48 Mil. Overall, Beijing Health Guard Biotechnology has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Health Guard Biotechnology's EBIT compare to VRTX and REGN?
Beijing Health Guard Biotechnology's EBIT of ¥-507.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Beijing Health Guard Biotechnology. Beijing Health Guard Biotechnology's current EBIT is ¥-507.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Health Guard Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Beijing Health Guard Biotechnology (BJSE:920575) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥7.92, compared to a current price of ¥5.59 — trading 29.4% below its estimated fair value. The current EBIT is ¥-507.48 Mil. Beijing Health Guard Biotechnology's overall GF Score™ is 47/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Beijing Health Guard Biotechnology (BJSE:920575), the current EBIT is ¥-507.48 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Health Guard Biotechnology (BJSE:920575) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Health Guard Biotechnology stock appears to be undervalued.
The current stock price of ¥5.59 is trading 29.4% below its estimated GF Value™ of ¥7.92.
GuruFocus considers Beijing Health Guard Biotechnology to be Modestly Undervalued.
Key valuation signals for BJSE:920575:
EBIT: ¥-507.48 Mil
GF Value™: ¥7.92 vs. price of ¥5.59 (29.4% below fair value)
No single metric tells the full story. See the BJSE:920575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Health Guard Biotechnology Inc engages in the research, development, and industrialization of recombinant protein vaccines. It mainly develops HPV vaccines in China and also advances multiple innovative candidate vaccines for other infectious diseases. Its core pipeline product includes a trivalent and a nonavalent HPV vaccine.
47GF Score
Get the complete analysis for BJSE:920575
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920575 has been successfully added to your 
